Markets closed

Vertex Pharmaceuticals Incorporated

VRTX · Nasdaq

Analyst Consensus

Buy

27 analysts

$520

Current

—

Low

$581

Average

—

High

Average target implies +11.84% versus the current price.

Analyst Ratings Synthesis

The consensus is Buy from all 27 analysts, with a mean price target of $560. The supplied consensus does not report low or high targets, so target dispersion cannot be measured, and it names neither the most nor least bullish analyst. No attributable analyst rating or price-target actions are provided for the week, preventing a firm-level revision read. The company, however, raised its 2026 sales outlook, supported by cystic-fibrosis growth, newer-product contributions and a planned renal launch. The substantive debate behind the available view is whether that operating momentum and diversification outweigh the 1.25% Q2 earnings miss and the integration risk from the Crinetics deal.

Rating Actions

No individual rating actions have been captured for VRTXyet. Consensus figures above come from Nasdaq's aggregate feed.

Rating actions are extracted from published reporting. Each row links to its source.

Research Reports

Links to freely available third-party research. Outlook labels are our classification of each article's stance, not a rating of our own.

Covering Firms

ARGUS RESEARCH

B OF A GLBL RES

BAIRD R W

BARCLAYS CAPITA

BMO CAPITAL MKT

CANACCORD GENUI

CANTOR FITZGERA

DBS BANK

EVERCORE ISI

GUGGENHEIM SEC.

H C WAINWRIGHT

JEFFERIES & CO.

JP MORGAN SECUR

LEERINK PARTNRS

MAXIM GROUP,LLC

MORGAN STANLEY

OPPENHEIMER HLD

PIPER SANDLER

RAYMOND JAMES

RBC CAPITAL

SANFORD BERNSTE

STIFEL NICOLAUS

TD COWEN

TRUIST SECURITI

WELLS FARGO SEC

WILLIAM BLAIR

ZACKS RESEARCH

Symbol: VRTX
Type: Stock
Sector: Health Care
Industry: Pharmaceutical Preparations
Exchange: Nasdaq

Vertex is a global biotechnology company that invests in scientific innovation to create transformative medicines for people with serious diseases and conditions. The company has approved therapies for cystic fibrosis, sickle cell disease, transfusion-dependent beta thalassemia, acute pain and acromegaly, and it continues to advance clinical and research programs in these areas. Vertex also has a robust clinical pipeline of investigational therapies across a range of modalities in other serious diseases where it has deep insight into causal human biology, including IgA nephropathy, neuropathic pain, APOL1-mediated kidney disease, primary membranous nephropathy, congenital adrenal hyperplasia, ACTH-dependent Cushing's syndrome, autosomal dominant polycystic kidney disease, type 1 diabetes, generalized myasthenia gravis, and myotonic dystrophy type 1. Vertex was founded in 1989 and has its global headquarters in Boston, with international headquarters in London.

Key Issues

Bullish view

Rising contributions from newer products, continued cystic-fibrosis growth and a near-term renal launch support Vertex’s diversification push and helped drive a higher 2026 sales outlook.

Bearish view

The cystic-fibrosis franchise remains the company’s main revenue engine, while newer products are still described as rising contributors rather than established businesses, leaving diversification execution-dependent.

Analyst Consensus

See all

Buy

27 analysts

$520

Current

—

Low

$581

Average

—

High

Average target implies +11.84% versus the current price.

Earnings History

BeatMissNo estimate

Vertex Pharmaceuticals Incorporated

Analyst Consensus

Analyst Ratings Synthesis

Rating Actions

Research Reports

Covering Firms

Peers